IBTROZI® (Taletrectinib)

The FDA on June 11, 2025, approved IBTROZI®, a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive Non-Small Cell Lung Cancer (NSCLC). IBTROZI® is a product of Nuvation Bio Inc.